Catalyst Crew Technologies Corp. (OTC: CCTC) announced that it has submitted a corporate action request to the Financial Industry Regulatory Authority (FINRA) seeking approval to change its corporate name to LataMed AI Corp. and its trading symbol to reflect the company's strategic shift toward artificial intelligence-enabled healthcare technology. The proposed changes, approved by the board of directors and the majority shareholder, do not involve any reverse stock split, forward stock split, recapitalization, or change to the company's capital structure. The outstanding share count will remain unchanged, and no action is required by existing shareholders.
According to the company's press release, the name change is intended to better align with its current strategic direction, which focuses on healthcare analytics and technology-enabled healthcare services infrastructure, initially targeting Latin America. Dr. Kevin Rodan Levy, CEO, emphasized that there is no change to the capital structure and that the proposed name change aims to align the company's public identity with its healthcare technology strategy and long-term market focus.
Upon FINRA approval, Catalyst Crew Technologies plans to file a Certificate of Amendment with the Nevada Secretary of State to effect the name change. The new name and symbol would become effective after completing corporate filings and publication by FINRA on the Daily List. However, the company cautioned that no assurance can be given regarding FINRA's approval, the requested new trading symbol, or the timing of any such approval.
Catalyst Crew Technologies is an artificial intelligence-driven healthcare technology company focused on developing scalable digital health solutions for emerging markets, with an initial emphasis on Latin America. The company is actively executing its strategic transition into AI-enabled healthcare through technology development initiatives, strategic partnerships, and targeted acquisitions, building an integrated healthcare technology platform to address the demand for modernized healthcare delivery systems in emerging markets.
As a development-stage enterprise, the company has not generated revenues from its newly announced business direction. The press release includes forward-looking statements concerning business strategy, leadership initiatives, strategic transactions, operational execution, regulatory matters, and future operations, which are subject to risks and uncertainties. The company undertakes no obligation to update any forward-looking statements except as required by law.
For more information, visit https://catalystcrewai.com or review the company's filings with the U.S. Securities and Exchange Commission at www.sec.gov.
